TOP TEN perturbations for 38552_f_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38552_f_at
Selected probe(set): 225674_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38552_f_at (225674_at) across 6674 perturbations tested by GENEVESTIGATOR:
coronary artery disease study 2 / normal endothelial progenitor cell (133+) sample
Relative Expression (log2-ratio):2.8988895Number of Samples:9 / 3
| Experimental | coronary artery disease study 2 |
| 133+ endothelial progenitor cells obtained from patients with coronary artery disease (CAD) prior to exercise. CAD patients were enrolled in a cardiac rehabilitation program. Medical management was stable for at least 1 month prior to program participation. Baseline testing was performed after an overnight fast (except for water). | |
| Control | normal endothelial progenitor cell (133+) sample |
| 133+ endothelial progenitor cells obtained from healthy subjects. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.7483625Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead) / DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)
Relative Expression (log2-ratio):-2.4854298Number of Samples:55 / 39
| Experimental | DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead) |
| Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons. | |
| Control | DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead) |
| Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.4648762Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-2.4606495Number of Samples:5 / 6
| Experimental | colorectal adenoma study 2 |
| Laser microdissected human adenoma sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
lactic acid study 1 (hypoxia) / untreated breast epithelial cell sample
Relative Expression (log2-ratio):-2.447217Number of Samples:3 / 3
| Experimental | lactic acid study 1 (hypoxia) |
| Breast epithelial cells exposed to 25mM lactic acid of pH6.7 and 2% hypoxia. ATC code: | |
| Control | untreated breast epithelial cell sample |
| Breast epithelial cells in control media under normoxia. |
tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.4067822Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
DLBCL study 4 (ABC DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (ABC DLBCL; baseline; CHOP; alive)
Relative Expression (log2-ratio):2.220377Number of Samples:54 / 19
| Experimental | DLBCL study 4 (ABC DLBCL; baseline; RCHOP; alive) |
| Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they were alive. | |
| Control | DLBCL study 4 (ABC DLBCL; baseline; CHOP; alive) |
| Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they were alive. |
DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)
Relative Expression (log2-ratio):2.179679Number of Samples:16 / 33
| Experimental | DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead) |
| Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons. | |
| Control | DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead) |
| Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons. |
DLBCL study 4 (GCB DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; alive)
Relative Expression (log2-ratio):2.1739693Number of Samples:91 / 43
| Experimental | DLBCL study 4 (GCB DLBCL; baseline; RCHOP; alive) |
| Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they were alive. | |
| Control | DLBCL study 4 (GCB DLBCL; baseline; CHOP; alive) |
| Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they were alive. |